NCT05042791: A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Radiation therapy, Tyrosine-kinase inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one measurable brain lesion
Exclusions: Patients with extensive leptomeningeal metastasis; Patients with brain metastases within 5 mm of the hippocampus; Patients with previous treatment of a tyrosine kinase inhibitor ((e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib)

Comments are closed.

Up ↑